NCT05645107: A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants with HGG and Recurrent or Severe Infections Associated with B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma |
|
|
| Recruiting | 3 | 386 | Europe, US, RoW | Xembify, Immune Globulin Subcutaneous (Human), 20% (IGSC 20%), Placebo, 0.9% Normal Saline | Grifols Therapeutics LLC | Hypogammaglobulinemia, Bacterial Infections, B-cell Chronic Lymphocytic Leukemia, Multiple Myleoma, Non-Hodgkin Lymphoma | 05/26 | 06/26 | | |
